The Investor Relations website contains information about PDL BioPharma, Inc.'s business for stockholders, potential investors, and financial analysts.

Email Alerts For Investor updates on the PDL Biopharma dissolution process, please sign up here.

Aug 18, 2023 · The Investor Relations website contains information about PDL BioPharma, Inc.'s business for stockholders, potential investors, and financial analysts.

Mr. Monnet brings the Board of Directors of PDL BioPharma a strong understanding of the pharmaceutical and biotechnology industries and experience in the commercialization of pharmaceutical products.

Mar 5, 2024 · led suit against Eli Lilly and Company in the Southern District of Indiana in December of 2023. Our suit alleges anticipatory breach of contract by Eli Lilly and requests a declaratory judgment that Eli Lilly’s humanized antibody drug for treatment of Alzheimer’s Disease, donanemab, is a “Licensed Product” under the Development and ...

PDL BioPharma, Inc.

Sep 30, 2020 · INCLINE VILLAGE, Nev., Nov. 11, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.

INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company's common stock from the Nasdaq Global Select Market ("Nasdaq").

INCLINE VILLAGE, Nev., Feb. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital Management LP (together with its affiliates, "Engine"), which owns approximately 5.5% of the Company's outstanding shares, pursuant to which Alan L ...

INCLINE VILLAGE, Nev., Dec. 9, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that it has completed the strategic review process that it initiated in September.